- Home
- AMGN vs SPGI Comparison
AMGN vs SPGI Comparison
Compare AMGN & SPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- SPGI
- Stock Information
- Founded
- AMGN 1980
- SPGI 1860
- Country
- AMGN United States
- SPGI United States
- Employees
- AMGN N/A
- SPGI N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- SPGI Finance: Consumer Services
- Sector
- AMGN Health Care
- SPGI Finance
- Exchange
- AMGN Nasdaq
- SPGI Nasdaq
- Market Cap
- AMGN 156.2B
- SPGI 142.3B
- IPO Year
- AMGN N/A
- SPGI N/A
- Fundamental
- Price
- AMGN $265.86
- SPGI $507.61
- Analyst Decision
- AMGN Buy
- SPGI Strong Buy
- Analyst Count
- AMGN 19
- SPGI 15
- Target Price
- AMGN $324.37
- SPGI $588.43
- AVG Volume (30 Days)
- AMGN 2.7M
- SPGI 1.2M
- Earning Date
- AMGN 05-01-2025
- SPGI 04-29-2025
- Dividend Yield
- AMGN 3.58%
- SPGI 0.76%
- EPS Growth
- AMGN 56.16
- SPGI 42.93
- EPS
- AMGN 10.94
- SPGI 12.73
- Revenue
- AMGN $34,126,000,000.00
- SPGI $14,494,000,000.00
- Revenue This Year
- AMGN $7.19
- SPGI $7.59
- Revenue Next Year
- AMGN $2.37
- SPGI $7.24
- P/E Ratio
- AMGN $24.29
- SPGI $39.84
- Revenue Growth
- AMGN 15.56
- SPGI 12.99
- 52 Week Low
- AMGN $253.30
- SPGI $419.49
- 52 Week High
- AMGN $346.85
- SPGI $545.39
- Technical
- Relative Strength Index (RSI)
- AMGN 34.80
- SPGI 60.49
- Support Level
- AMGN $268.81
- SPGI $500.07
- Resistance Level
- AMGN $291.61
- SPGI $514.78
- Average True Range (ATR)
- AMGN 7.54
- SPGI 10.26
- MACD
- AMGN -0.76
- SPGI 4.07
- Stochastic Oscillator
- AMGN 0.76
- SPGI 88.88
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.